Researchers in China have demonstrated interferon-alpha (IFN-a) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-a priming was shown to promote lipid uptake and foam ce…
A newly designed tool is helping researchers shed light on the quality of life (QoL) of children with lupus around the world, according to research presented at the American College of Rheumatology (ACR) annual meeting, held Nov. 7-11, in Atlanta.
…
The benefits of collaborative, multidisciplinary care of patients with complex autoimmune diseases like lupus and multiple sclerosis are just beginning to be appreciated by physicians. Hospital for Special Surgery in New York will present evidence o…
A cousin to the anti-anxiety drug Valium has been shown in mice to reduce some of the symptoms associated with lupus. Lupus is an autoimmune condition in which the immune system attacks the body’s own tissues. “The best available therapies for lupus haven’t changed for many, many years,” says U-M’s Gary D. Glick, Ph.D., one of the lead authors on the study. “It’s a disease where the mechanisms that normally prevent the immune system from attacking components of one’s own body are defective. Because we do not yet understand what triggers lupus, it has been very difficult to develop lupus-specific therapies.”